1. Xavier Montalban. 2024 revisions of the McDonald criteria. 2024 ECTRIMS
2. Ludwig Kappos, et al. Long-term progression independent of relapse activity rates and associated prediction model based on machine learning in phase 3 and open-label extension studies of ozanimod in relapsing multiple sclerosis. 2024 ECTRIMS
3. Krzysztof W. Selmaj, et al. Safety patterns over up to 8 years with ozanimod in patients with relapsing multiple sclerosis: final results from the DAYBREAK open-label extension study. 2024 ECTRIMS
4. Jeffrey A. Cohen, et al. Whole brain, cortical grey matter, and thalamic volume changes during 5–7 years of ozanimod in relapsing MS: final results from the DAYBREAK open-label extension study. 2024 ECTRIMS
5. Iris-Katharina Penner, et al. Maintenance of early improvement on the Symbol Digit Modalities Test associated with long-term ozanimod use: final analysis from the phase 3 SUNBEAM and DAYBREAK extension trials. 2024 ECTRIMS
6. Mathias Buttmann, et al. One-year real-world clinical effectiveness and safety of ozanimod for relapsing-remitting multiple sclerosis in Germany: an interim analysis of the prospective, noninterventional OzEAN study. 2024 ECTRIMS
7. E. Signoriello, et al. Switch from fingolimod to ozanimod for safety or intolerance reasons. 2024 ECTRIMS
8. Nixon R, Bergvall N, Tomic D, Sfikas N, Cutter G, Giovannoni G. No evidence of disease activity: indirect comparisons of oral therapies for the treatment of relapsing-remitting multiple sclerosis. Adv Ther. 2014;31(11):1134-1154.
9. Ludwig Kappos, Giancarlo Comi, Krzysztof W. Selmaj, et al. Evaluating No Evidence of Disease Activity in Patients With Relapsing Multiple Sclerosis: Post Hoc Analysis of the Phase 3 RADIANCE and Open-Label Extension Studies of Ozanimod. 2022 AAN P012.
